ClinicalTrials.gg
CompletedNCT01229735Updated Aug 15, 2017Results posted

Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures

A Phase 4 interventional study of Levetiracetam and Topiramate in Epilepsy, sponsored by UCB Korea Co., Ltd.. Completed at 24 sites in Korea, Republic of. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by UCB Korea Co., Ltd. (part of UCB S.A.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
10th of 60
343 · median 94
Started
2010
with 3 others
Phase 4
13 of 60
1 open now
Registered
37th of 60
by date

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 10th largest by enrollment, is one of 4 that started in 2010, is one of 13 in phase 4, and was the 37th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

To assess the long-term effects of levetiracetam on retention rate in subjects with refractory partial onset seizure that are not fully controlled with 1 to 3 concomitant antiepileptic drugs, compared to topiramate as add-on therapy during 52 weeks.

03

Conditions studied

  • Epilepsy

Keywords

  • levetiracetam
  • topiramate
  • epilepsy
  • partial seizures
04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects from 16 to 80 years, inclusive. Subjects under 20 years may only be included where legally permitted and ethically accepted
  • Subjects with epilepsy with partial onset seizure classifiable according to the International League Against Epilepsy (ILAE).
  • Subjects having at least 2 partial onset seizures whether or not secondarily generalized during the 8 weeks historical baseline preceding V1 according to ILAE classification
  • Subjects having at least 1 partial onset seizures whether or not secondarily generalized per 4 weeks preceding V2 according to ILAE classification
  • Subjects with each interval of partial onset seizures less than 6 weeks during entire 12 weeks (8 weeks preceding V1 and 4 weeks preceding V2)
  • Subjects being uncontrolled while treated by 1 to 3 permitted concomitant AEDs.
  • Permitted concomitant AEDs having been stable and at optimal dosage for the subject from at least 4 week before V1 and during 4 weeks preceding V2 and expected to be kept stable during the Treatment Period.

Exclusion criteria

Exclusion Criteria:

  • Subjects presenting any generalized epilepsies classified as type II according to the ILAE classification (ref to publication from 1981)
  • Subjects suffering from epilepsies and syndromes undetermined whether focal or generalized (classification III according to the ILAE classification)
  • Subjects suffering from special syndromes (classification IV according to the ILAE classification)
  • History or occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before V2.
  • Presence of exclusively type IA non-motor seizures.
  • History or presence of status epilepticus within last 3 months preceding V1 or during Baseline
  • History or presence of known pseudo-seizures
  • Subjects who are currently on vigabatrin. (Subjects who received vigabatrin in the past and have a normal visual field test are allowed.)
  • Subject taking 1 or more of the following medications on a regular basis within 28 days prior to Visit 1: antipsychotics drugs, and psychostimulant (amphetamine derivatives)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    250 mg and 500 mg levetiracetam tablet; titration from 1000 mg/day (500 mg bid) to 3000 mg/day (1500 mg bid) levetiracetam with treatment duration up to 52 weeks

    Drug: Levetiracetam

  • Active comparator
    Topiramate

    25 mg and 100 mg topiramate tablet; titration from 100 mg/day (50 mg bid) to 400 mg/day (200 mg bid) topiramate with treatment duration up to 52 weeks

    Drug: Topiramate

Interventions

  • 250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks

    Also known as: Keppra

  • 25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Continuing the Allocated Investigational Treatment From the First Study Treatment Intake to Week 52, After the Beginning of Investigational Treatment With Levetiracetam Compared to Topiramate

    Time frame: From Baseline to Week 52

Secondary outcomes

  1. Number of Subjects With at Least One Adverse Event Reported During the Trial Period From Baseline to Week 52

    Time frame: From Baseline to Week 52

  2. Time From the First Study Treatment Intake to Drug Discontinuation Due to Adverse Event (AE)

    Time frame: From Baseline to Week 52

  3. Median Percent Reduction in the Weekly Partial Onset Seizure (POS) Frequency From Baseline During the Total Treatment Period From Baseline to Week 52

    Reduction from baseline was defined as baseline value minus post-baseline value and therefore is the negative of the change from baseline value.

    Time frame: From Baseline to Week 52

  4. Responders Defined as Number of Subjects With at Least 50 % Reduction in the Weekly POS Frequency From Baseline During the Total Treatment Period From Baseline to Week 52

    Time frame: From Baseline to Week 52

07

Results

Posted Feb 12, 2016

Participant flow

447 subjects were screened, 343 subjects were randomized.

Participant flow — Overall Study
MilestoneLevetiracetamTopiramate
Started177166
Completed111100
Not completed6666
Withdrew: Lack of efficacy88
Withdrew: Protocol violation138
Withdrew: Lost to follow-up02
Withdrew: Withdrawal by subject1817
Withdrew: Other reason1310
Withdrew: Sae, non-fatal04
Withdrew: Ae, non-serious non-fatal1317
Withdrew: Sae, non-fatal+ae, non-serious non-fatal10

Outcome measures

PrimaryPercentage of Subjects Continuing the Allocated Investigational Treatment From the First Study Treatment Intake to Week 52, After the Beginning of Investigational Treatment With Levetiracetam Compared to Topiramate
Time frame:
From Baseline to Week 52
Reported as:
Number · percentage of subjects
Percentage of Subjects Continuing the Allocated Investigational Treatment From the First Study Treatment Intake to Week 52, After the Beginning of Investigational Treatment With Levetiracetam Compared to Topiramate
percentage of subjectsLevetiracetam (Full Analysis Set)Topiramate (Full Analysis Set)
Percentage of Subjects Continuing the Allocated Investigational Treatment From the First Study Treatment Intake to Week 52, After the Beginning of Investigational Treatment With Levetiracetam Compared to Topiramate59.156.6
Statistical analysis
  • Levetiracetam (Full Analysis Set) vs Topiramate (Full Analysis Set) · Regression, Logistic · p = =0.7007 (P-value is from likelihood ratio test of treatment group regression coefficient against 0.) · Odds ratio (or): 1.1 · 95% CI 0.7 to 1.7
SecondaryNumber of Subjects With at Least One Adverse Event Reported During the Trial Period From Baseline to Week 52
Time frame:
From Baseline to Week 52
Reported as:
Number · Participants
Number of Subjects With at Least One Adverse Event Reported During the Trial Period From Baseline to Week 52
ParticipantsLevetiracetamTopiramate
Number of Subjects With at Least One Adverse Event Reported During the Trial Period From Baseline to Week 52125128
SecondaryTime From the First Study Treatment Intake to Drug Discontinuation Due to Adverse Event (AE)
Time frame:
From Baseline to Week 52
Reported as:
Median · month
Time From the First Study Treatment Intake to Drug Discontinuation Due to Adverse Event (AE)
monthLevetiracetamTopiramate
Time From the First Study Treatment Intake to Drug Discontinuation Due to Adverse Event (AE)NA (NA to NA)NA (NA to NA)
SecondaryMedian Percent Reduction in the Weekly Partial Onset Seizure (POS) Frequency From Baseline During the Total Treatment Period From Baseline to Week 52

Reduction from baseline was defined as baseline value minus post-baseline value and therefore is the negative of the change from baseline value.

Time frame:
From Baseline to Week 52
Reported as:
Median · percent reduction
Median Percent Reduction in the Weekly Partial Onset Seizure (POS) Frequency From Baseline During the Total Treatment Period From Baseline to Week 52
percent reductionLevetiracetam (Full Analysis Set)Topiramate (Full Analysis Set)
Median Percent Reduction in the Weekly Partial Onset Seizure (POS) Frequency From Baseline During the Total Treatment Period From Baseline to Week 5274.47 (38.00 to 96.28)67.86 (29.21 to 87.24)
SecondaryResponders Defined as Number of Subjects With at Least 50 % Reduction in the Weekly POS Frequency From Baseline During the Total Treatment Period From Baseline to Week 52
Time frame:
From Baseline to Week 52
Reported as:
Number · responders
Responders Defined as Number of Subjects With at Least 50 % Reduction in the Weekly POS Frequency From Baseline During the Total Treatment Period From Baseline to Week 52
respondersLevetiracetam (Full Analysis Set)Topiramate (Full Analysis Set)
Responders Defined as Number of Subjects With at Least 50 % Reduction in the Weekly POS Frequency From Baseline During the Total Treatment Period From Baseline to Week 52120107

Adverse events

Collected over Adverse Events (AEs) were collected from Visit 1 (Week -4) until final Visit 12 (Week 53).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam—10/177 (5.6%)86/177 (48.6%)
Topiramate—15/166 (9%)91/166 (54.8%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventLevetiracetamTopiramate
SeizureNervous system disorders1/1775/166
DizzinessNervous system disorders2/1770/166
Duodenal ulcerGastrointestinal disorders0/1771/166
Gastrooesophageal reflux diseaseGastrointestinal disorders0/1771/166
Pancreatitis acuteGastrointestinal disorders0/1771/166
PneumoniaInfections and infestations0/1771/166
Joint dislocationInjury, poisoning and procedural complications0/1771/166
Radius fractureInjury, poisoning and procedural complications0/1771/166
Spinal compression fractureInjury, poisoning and procedural complications0/1771/166
HyperglycaemiaMetabolism and nutrition disorders0/1771/166
Most frequent other events
Showing 10 of 11
Most frequent other events
EventLevetiracetamTopiramate
SomnolenceNervous system disorders36/17720/166
DizzinessNervous system disorders30/17724/166
Decreased appetiteMetabolism and nutrition disorders3/17726/166
HeadacheNervous system disorders17/17724/166
NasopharyngitisInfections and infestations24/17716/166
Weight decreasedInvestigations3/17717/166
ParaesthesiaNervous system disorders2/17716/166
NauseaGastrointestinal disorders9/17710/166
Memory impairmentNervous system disorders1/1779/166
DyspepsiaGastrointestinal disorders9/1777/166

Baseline characteristics

The Baseline Characteristics refers to the Safety Set which consists of all subjects who were randomized and received at least 1 dose of trial medication.

Age, Categorical
Age, Categorical(Participants)LevetiracetamTopiramateTotal Title
<=18 years404
Between 18 and 65 years165162327
>=65 years8412
Age, Continuous
Age, Continuous(years)LevetiracetamTopiramateTotal Title
Mean40.9 ± 13.639.7 ± 11.840.3 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)LevetiracetamTopiramateTotal Title
Female7164135
Male106102208
08

Study locations

24 sites
  • 14
    Busan, Korea, Republic of
  • 21
    Busan, Korea, Republic of
  • 8
    Busan, Korea, Republic of
  • 9
    Busan, Korea, Republic of
  • 12
    Daegu, Korea, Republic of
  • 13
    Daegu, Korea, Republic of
  • 10
    Daejeon, Korea, Republic of
  • 25
    Daejeon, Korea, Republic of
  • 15
    Gwangju, Korea, Republic of
  • 7
    Incheon, Korea, Republic of
  • 11
    Kyunggi-Do, Korea, Republic of
  • 19
    Kyunggi-do, Korea, Republic of
  • 23
    Kyunggi-Do, Korea, Republic of
  • 24
    Kyunggi-Do, Korea, Republic of
  • 16
    Seoul, Korea, Republic of
  • 17
    Seoul, Korea, Republic of
  • 18
    Seoul, Korea, Republic of
  • 1
    Seoul, Korea, Republic of
  • 2
    Seoul, Korea, Republic of
  • 3
    Seoul, Korea, Republic of
  • 4
    Seoul, Korea, Republic of
  • 5
    Seoul, Korea, Republic of
  • 6
    Seoul, Korea, Republic of
  • 22
    Ulsan, Korea, Republic of
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2010
First posted
Oct 28, 2010
Start
Nov 2010
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Feb 12, 2016
Last update
Aug 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01229735
Responsible party
Sponsor
First posted
Oct 28, 2010
Start date
Nov 2010
Primary completion
May 2015
Completion
May 2015
Results posted
Feb 12, 2016
Last update
Aug 15, 2017

Study contacts

UCB Clinical Trial Call Center
study director · 1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion